Drug Trial Radar · NCT06176768
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Oct 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Dec 6, 2023
Primary completion
Apr 1, 2025
Study completion May 6, 2025
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Dec 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.
Conditions
- Plaque Psoriasis
Interventions
LY3972406Drug
Administered orally
PlaceboDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75)Time frame: Week 12
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Dermatology Research Associates
Los Angeles, California
Clinical Science Institute
Santa Monica, California
Driven Research
Coral Gables, Florida
Conquest Research
Winter Park, Florida
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
Schweiger Dermatology Group
Hackensack, New Jersey
Metropolitan Dermatology - Clark
Kenilworth, New Jersey
Accellacare - Winston-Salem
Winston-Salem, North Carolina
Remington-Davis, Inc
Columbus, Ohio
DermDox Centers for Dermatology
Camp Hill, Pennsylvania
Center for Clinical Studies
Houston, Texas
Austin Institute for Clinical Research
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.